Incidence of DR at Each Landmark Time Assessment in OPTiM Patients Treated with Talimogene Laherparepvec and GM-CSFa

Landmark Time, MonthsPatients Alive, nDR Achieved, nHR for OS in Patients with DR Versus Those Without, HR (95% CI)Adjusted HR for OS in Patients with DR Versus Those Without HR (95% CI)b
9335220.07 (0.01–0.48)0.07 (0.01–0.54)
12304360.05 (0.01–0.33)0.05 (0.01–0.35)
18236500.11 (0.03–0.44)0.11 (0.03–0.47)

DR durable response, GM-CSF granulocyte macrophage-colony stimulating factor, HR hazard ratio, ITT intent-to-treat, OS overall survival

aAnalysis was performed in ITT population of OPTiM

bAdjusted for disease stage (stage IIIB, IIIC, IVM1a versus stage IVM1b, IVM1c) and line of therapy (first-line versus second-line)